Recent developments highlight regulatory progress with FDA clearance of first-cycle review for KETAFREE™ ANDA, near FDA decision on preservative-free ketamine, FDA approval of expanded access protocol for NRX-101, and clinical advancements through HOPE Therapeutics including AI-guided TMS treatments. The company reported Q2 2026 financial results showing a net loss and liquidity status.

• NRX Pharmaceuticals reported a net loss for Q2 2026 and missed revenue estimates [N1].
• FDA cleared the first-cycle review of the preservative-free ketamine ANDA (KETAFREE™); approval awaits vial certification [N3].
• The company is nearing FDA decision on preservative-free ketamine following review clearance [N2].
• HOPE Therapeutics, a subsidiary, began patient treatment using AI-guided TMS systems [N4].
• NRX-101 received FDA approval for an intermediate population expanded access protocol [N5].
• The company held a Q1 2026 earnings call discussing clinical and regulatory progress [N6][N8].
• NRX Pharmaceuticals was highlighted among top biotech gainers as it neared FDA decision [N7].

NRX Pharmaceuticals has advanced multiple drug candidates targeting serious CNS disorders with regulatory designations that facilitate expedited review. The preservative-free ketamine formulations address safety concerns related to existing products and may capture significant market share in both generic and innovative ketamine markets. The company's use of real-world evidence to support NDA filings and its integration with HOPE Therapeutics' clinical network offering cutting-edge interventional psychiatry treatments could enhance patient access and adoption. FDA approvals for expanded access protocols and ongoing clinical trials, including novel TMS augmentation strategies, may broaden therapeutic indications and patient populations.

NRX Pharmaceuticals faces risks typical of clinical-stage biopharmaceutical companies, including regulatory uncertainties, potential delays or denials of FDA approvals for its drug candidates, and challenges in demonstrating clinical efficacy and safety. The company's liquidity ratios below 1 indicate potential funding needs to support ongoing operations and clinical trials. Market acceptance of preservative-free ketamine formulations and novel combination therapies is uncertain. Competition from established ketamine products and other CNS disorder treatments may limit market penetration. The success of HOPE Therapeutics' clinical operations depends on patient adoption and reimbursement environments. Any adverse regulatory or clinical outcomes could materially impact the company's prospects.

NRX Pharmaceuticals' moat is based on its proprietary preservative-free ketamine formulations, including KETAFREE™ and NRX-100, which have potential patent protection and regulatory exclusivity. The company's focus on NMDA receptor modulation and neuroplasticity-targeted therapeutics addresses significant unmet medical needs in central nervous system disorders. FDA Fast Track and Breakthrough Therapy designations support expedited development and potential market differentiation. The integration of drug development with HOPE Therapeutics' interventional psychiatry clinics, offering advanced treatments such as AI-guided TMS and novel protocols, provides a unique clinical delivery platform. The company's submission of a citizen petition to remove toxic preservatives from ketamine formulations may further differentiate its products in the market. However, as a clinical-stage company, commercial success depends on regulatory approvals and market adoption.

• Regulatory Approval Risk: The company’s drug candidates require FDA approval, which involves uncertainties and potential delays that could impact commercialization timelines.
• Financial and Liquidity Risk: Liquidity ratios below 1 as of June 30, 2026, indicate potential challenges in funding operations and clinical development without additional financing.
• Market Acceptance Risk: Adoption of preservative-free ketamine formulations and novel therapies depends on physician and patient acceptance, which is uncertain.
• Competition Risk: Competition from existing ketamine products and other CNS disorder treatments may limit market share and pricing power.
• Clinical Trial Risk: Clinical trials, including those combining NRX-101 with TMS, may not demonstrate sufficient safety or efficacy to support regulatory approvals or market adoption.

• NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders including suicidal depression, chronic pain, PTSD, and schizophrenia [S1].
• The company operates through its wholly-owned subsidiary NeuroRx, Inc. and is the founder and majority owner of HOPE Therapeutics, Inc., a medical services company providing interventional psychiatry care including neuroplastic drugs, TMS, digital therapeutics, and hyperbaric therapy [S1].
• NRX's drug development focuses on drugs modulating the NMDA receptor to enhance neuroplasticity [S1].
• The company has three lead drug candidates: NRX-100 (preservative-free ketamine for intravenous infusion), KETAFREE™ (generic preservative-free ketamine), and NRX-101 (oral fixed dose combination of D-cycloserine and lurasidone) [S1].
• KETAFREE™ ANDA was filed with priority review requested in September 2025; FDA communications indicate no significant deficiencies and bioequivalence to the reference drug KETALAR®; commercial sales anticipated with FDA approval in Q3 2026 [S1].
• NRX-100 NDA filing is in process, with Fast Track Designation for treatment of suicidal ideation in depression including bipolar depression; real-world evidence from 65,000 patients treated with IV ketamine is being submitted to FDA [S1].
• NRX-101 NDA filing has been initiated with Breakthrough Therapy Designation; the company requests rolling review for accelerated approval for bipolar depression patients with suicidal ideation [S1].
• HOPE Therapeutics operates multiple clinics in Florida offering interventional psychiatry treatments including ketamine infusion, TMS, and Spravato®; first clinical revenue recorded in Q4 2025; plans to expand clinic locations [S1].
• HOPE has begun patient treatment using AI-guided TMS systems and offers a one-day TMS protocol combined with D-cycloserine showing high response and remission rates [N4][S1].
• NRX-101 received FDA approval for an intermediate population expanded access protocol [N5].
• The company reported a net loss of $16.52 million for the quarter ended June 30, 2026, with basic EPS of -$0.44 [S2].
• As of June 30, 2026, NRX had cash and equivalents of $26.686 million, current assets of $29.158 million, current liabilities of $33.874 million, a current ratio of 0.86, and a cash ratio of 0.79 [S2].
• Recent news highlights include FDA clearance of first-cycle review of KETAFREE™ ANDA, near FDA decision on preservative-free ketamine, and ongoing clinical and regulatory progress [N1][N2][N3].
• The company has submitted a citizen petition to remove benzethonium chloride, a toxic preservative, from all commercial ketamine presentations [S1].
• NRX has received Fast Track Designation expansions and FDA meetings to align on submission strategies combining clinical trials and real-world evidence [S1].
• The company has engaged in financing activities including at-the-market offerings and registered direct offerings during 2025 to support operations and acquisitions [S1].
• Leadership changes include appointment of Jonathan C. Javitt, MD, MPH as permanent CEO in January 2026 [S1].